SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients (CISPD-2)

  • STATUS
    Recruiting
  • End date
    Oct 22, 2023
  • participants needed
    36
  • sponsor
    Second Affiliated Hospital, School of Medicine, Zhejiang University
Updated on 15 February 2022
fluorouracil
metastasis
liver metastasis
gemcitabine
stereotactic body radiation therapy
cancer chemotherapy
antineoplastic
folfirinox
recurrent pancreatic cancer

Summary

When gemcitabine based chemo and fluorouracil based chemo regimes are failed in late-stage or recurrent pancreatic cancer patients, there is no alternative options. Anti-PD-1 antibody has became a promising anti-cancer drug. While it showed limited efficacy in pancreatic cancer. Stereotactic Body Radiotherapy has been a new method to locally treat metastatic cancer. This study is aimed to evaluate the safety and efficacy of the combination of SBRT and anti-PD-1 antibody in late-stage or recurrent pancreatic caner who failed in second-line chemotherapy.

Description

Pancreatic cancer is a kind of cancer with poor prognosis. Nowadays, recommended treatment for late-stage or recurrent pancreatic cancer patients are fluorouracil based chemotherapy (such as FOLFIRINOX) and gemcitabine based chemotherapy. When these two chemo regimes are failed, however, there is no alternative options. With the improvement of immune therapy, anti-PD-1 antibody has became a promising anti-cancer drug. While it showed limited efficacy in pancreatic cancer. Stereotactic Body Radiotherapy (SBRT) has been a new method to locally treat metastatic cancer. And previous studies showed that SBRT may enhance the efficacy of immunotherapy. So this study is amed to evaluate the safety and efficacy of the combination of SBRT and anti-PD-1 antibody in late-stage or recurrent pancreatic caner who failed in second-line chemotherapy.

Details
Condition Pancreatic Cancer
Treatment SBRT, anti-PD-1 antibody
Clinical Study IdentifierNCT03716596
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Last Modified on15 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

18 years
Histopathology or cytology confirmed pancreatic cancer
Patients failed in second-line chemotherapy: patients have failed in gemcitabine-based chemotherapy and also failed in fluorouracil-based chemotherapy (like FOLFIRINOX), failed in combination of chemotherapy and radiotherapy; patients may have failed in immune therapy (including anti-PD-1 antibody)
\. Eastern cooperative oncology group physical fitness score was 0~2
\. The main organs are functional and meet the following criteria (Routine blood tests were in accordance with the following criteria)
White blood cell (WBC) 3.5 x 10^6 /L, neutrophil >1.5 x10^9/L
platelet (PLT) 50 x10^9/L
hemoglobin (HB) 80 g/L
total bilirubin (TB) 1.5 x ULN (upper limit of normal value). 5Alanine transaminase (ALT) and aspartate aminotransferase (AST) 2 x ULN (upper limit of normal value) (if there is liver metastasis, 5 x ULN)
Serum creatinine (Scr) 1.5 x ULN 7) Albumin (ALB) 3 g/dL
\. Patients will be informed consent, and understand and are willing to cooperate with the trial and sign related documents

Exclusion Criteria

\. In the first 4 weeks before the start of the study, they took part in other drug clinical trials
\. Before the start of the study, they were diagnosed as immune deficiency diseases or need systemic steroid therapy
\. In the first 4 weeks before the start of the study, they took anti-tumor immune therapy; or didn't recovery from the adverse effects caused by the anti-tumor immune therapy
\. In the first 2 weeks before the start of the study, they took chemotherapy, small molecule targeting therapy, and radiotherapy; or didn't recovery from the adverse effects caused by these therapies
\. Has had active tuberculosis before
\. Has a history of malignant tumor, except for basal and skin squamous cell carcinoma, cervical carcinoma in situ and papillary thyroid carcinoma
\. Has central nervous system metastasis or meningeal metastasis
\. Has serious and uncontrollable internal diseases such as severe diabetes, severe hypertension, serious infection, congestive heart failure, ventricular fibrillation, coronary heart disease with obvious symptoms or myocardial infarction in the past 6 months
\. Has blood precancerous diseases, such as myelodysplastic syndrome
\. Has clinically relevant or preexisting interstitial lung diseases, such as noncommunicable pneumonia or pulmonary fibrosis, or evidence of interstitial lung diseases on baseline chest CT scans or chest x-rays
\. Past or physical examinations have found diseases of the central nervous system, with the exception of those that have been adequately treated (such as primary brain tumors, uncontrolled seizures or strokes with standard medication)
\. Has preexisting neuropathy at > level 1 (NCI CTCAE)
\. Allotransplantation requires immunosuppression therapy or other major immunosuppression therapy
\. Has a severe open wound, ulcer, or fracture
\. Systemic treatment is required for autoimmune diseases that have been active for the past 2 years.Alternative therapies are not systemic treatments
\. Has a history of non-infectious pneumonia requiring steroid therapy or active pneumonia.Has interstitial lung disease
\. Patients with active infections require systemic treatment
\. Patients with active hepatitis b or c are not included in liver lesions SBRT
\. Has vaccinate within 30 days before treatment.Including intranasal influenza vaccines, except seasonal influenza vaccines
\. Others: allergic history of similar drugs, pregnancy or lactation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note